IL33 and Alzheimer disease: Although this molecule is a good biomarker, a study assessing the efficacy, safety, and pharmacokinetic profile of itepekimab (REGN3500), an anti-IL33 antibody (Figure 2b), administered subcutaneously to adult patients with moderate-to-severe AD failed to reach significance in a phase 2b clinical trial [51].